



## Array BioPharma To Report Financial Results For The Fourth Quarter And Full Year Of Fiscal 2017 On August 9, 2017

August 3, 2017

BOULDER, Colo., Aug. 3, 2017 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the fourth quarter and full year of fiscal 2017 and hold a conference call to discuss those results on Wednesday, August 9, 2017. Ron Squarer, Chief Executive Officer, will lead the call.

**Date:** Wednesday, August 9, 2017  
**Time:** 9:00 a.m. Eastern Time  
**Toll-Free:** (844) 464-3927  
**Toll:** (765) 507-2598  
**Pass Code:** 44703107



**Webcast, including Replay and Conference Call Slides:**

<http://edge.media-server.com/m/p/af6yqtav>

### **About Array BioPharma**

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Eight registration studies are currently advancing related to seven Array-owned or partnered drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Cascadian Therapeutics).

**CONTACT:** Tricia Hugueto  
Array BioPharma Inc.  
(303) 386-1193  
[thugueto@arraybiopharma.com](mailto:thugueto@arraybiopharma.com)

View original content with multimedia: <http://www.prnewswire.com/news-releases/array-biopharma-to-report-financial-results-for-the-fourth-quarter-and-full-year-of-fiscal-2017-on-august-9-2017-300499225.html>

SOURCE Array BioPharma